-
Product Insights
Net Present Value Model: Valneva SE’s VLA-1553
Empower your strategies with our Net Present Value Model: Valneva SE's VLA-1553 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VLA-1553 in Chikungunya Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VLA-1553 in Chikungunya Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VLA-1553 in Chikungunya Fever Drug Details: VLA-1553 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBF-015 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBF-015 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBF-015 in Parkinson's Disease Drug Details: MBF-015 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VLA-15 in Lyme Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VLA-15 in Lyme Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VLA-15 in Lyme Disease Drug Details: VLA-15 (IC-15) is under development...
-
Company Insights
Innovation and Patenting activity of Valneva SE Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Valneva SE Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Track & Monitor
Innovation in pharma: attenuated virus vaccines
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s attenuated virus vaccines segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Sector Analysis
COVID-19 Vaccines Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2026
COVID-19 Vaccines Market Report Overview The sales of COVID-19 vaccines across the 7MM reached $25 billion in 2021 and consisted of Tour authorized products: Comirnaty, Spikevax, Vaxzevria, and Jcovden. the COVID-19 vaccines market declined across the 7MM in 2022 as most individuals completed primary vaccinations and received at least one dose of an updated bivalent mRNA booster vaccine. Overall, the COVID-19 vaccines market is expected to significantly decline across the 7MM during the forecast period, at a negative compound annual...
-
Company Profile
Valneva SE – Company Profile
Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of Lyme disease, Zika virus, Chikungunya and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and distribute its...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Net Present Value Model: VLA-1553
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VLA-1553 Drug Details VLA-1553 is under...